Details:
Eighteen MS patients were enrolled in this Phase II randomized, double-blind, placebo-controlled, parallel group, dose-finding trial that evaluated the safety and tolerability of two vafidemstat doses in relapse-remitting MS or secondary progressive MS patients.
Lead Product(s): Vafidemstat
Therapeutic Area: Immunology Product Name: ORY-2001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021